Pan-cancer analysis of <i>ARID1A</i> Alterations as Biomarkers for Immunotherapy Outcomes

Jiang, Tao; Chen, Xiaoxia; Su, Chunxia; Ren, Shengxiang; Zhou, Caicun

doi:10.7150/jca.41296

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2020; 11(4):776-780. doi:10.7150/jca.41296 This issue Cite

Research Paper

Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes

Tao Jiang^1,2,3, Xiaoxia Chen^1,3, Chunxia Su^1,3, Shengxiang Ren^1✉, Caicun Zhou^1✉

1. Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
2. Department of Pulmonary Medicine, Shanghai Respiratory Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
3. These authors contributed equally to this paper.

✉ Corresponding authors: Prof. Caicun Zhou, M.D., Ph.D., Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, No. 507, Zheng Min Road, Shanghai, 200433, P.R. China. Tel: +86 More

Citation:

Jiang T, Chen X, Su C, Ren S, Zhou C. Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes. J Cancer 2020; 11(4):776-780. doi:10.7150/jca.41296. https://www.jcancer.org/v11p0776.htm

Other styles

Abstract

ARID1A alterations would compromise mismatch repair pathway and increase the number of tumor-infiltrating lymphocytes and PD-L1 expression in some cancers, which would cooperate with immune checkpoint inhibitors (ICIs) treatment. However, a comprehensive analysis of ARID1A alteration frequency and its predictive value for ICI treatment outcome in cancers has not yet been investigated. Hence, we performed this pan-cancer analysis to evaluate the prevalence and predictive value of ARID1A alterations across >40,000 cases in multiple cancer types. We found a high frequency (6.2%) of ARID1A, which were associated with significantly higher tumor mutation burden level across various cancers. Importantly, patients with ARID1A alterations and advanced cancers had the substantially prolonged overall survival in ICI treatment cohort, suggesting it might be used to predict a survival benefit from ICI therapy across multiple cancer types. Notably, ARID1A alterations were correlated with markedly high immune infiltrates in endometrial, stomach and colon cancer. However, patients with ARID1A-mutant renal clear cell carcinoma had dramatically lower CD8⁺ T cell infiltrations than those without, indicating the association between ARID1A alterations and immune infiltrates was cancer-dependent. Collectively, our findings highlight the important value of ARID1A alterations as pan-cancer predictive biomarkers for ICI treatment.

Keywords: ARID1A, Immunotherapy, Biomarker, Pan-cancer.

Citation styles

APA

Jiang, T., Chen, X., Su, C., Ren, S., Zhou, C. (2020). Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes. Journal of Cancer, 11(4), 776-780. https://doi.org/10.7150/jca.41296.

ACS

Jiang, T.; Chen, X.; Su, C.; Ren, S.; Zhou, C. Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes. J. Cancer 2020, 11 (4), 776-780. DOI: 10.7150/jca.41296.

NLM

CSE

Jiang T, Chen X, Su C, Ren S, Zhou C. 2020. Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes. J Cancer. 11(4):776-780.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.